Current mRNA-based vaccines for COVID-19 from Pfizer/BioNTech and Moderna have been ... at other candidates for indications like flu, malaria, tuberculosis, rabies and respiratory syncytial ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Scientists have detected resistance to artemisinin, a key malaria drug, for the first time among children in Africa with ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Also Read: BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3 The analyst adds that the data for BNT327, including the latest findings presented at the European Society for Medical Oncology ...

BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. The German developer of RNA vaccines and immunotherapies said ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

The launch follows the arrival of the first shipment of 186,000 doses of the malaria vaccines to Sudan in October. The ...

The development and implementation of a malaria vaccine would constitute a major breakthrough for global health. Recently, numerous new candidates have entered clinical testing, following ...

However, production of the mRNA used in vaccines is hindered by its ... Oct. 23, 2024 — Maternal antibodies passed across the placenta can interfere with the response to the malaria vaccine ...